Clinical Trial Update: A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy [Phase 3]

View source ↗

Summary

This Phase 3 trial of tocilizumab in ankylosing spondylitis patients who failed TNF antagonist therapy was terminated. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• RoActemra (tocilizumab) (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Spondylitis, Ankylosing | Phase 3 | Status: TERMINATED | Results posted: 2013-01-17